Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Artigo em Inglês | MEDLINE | ID: mdl-28264852

RESUMO

The liver is crucial to pharmacology, yet substantial knowledge gaps exist in the understanding of its basic pharmacologic processes. An improved understanding for humans requires reliable and reproducible liver sampling methods. We compared liver concentrations of paritaprevir and ritonavir in rats by using samples collected by fine-needle aspiration (FNA), core needle biopsy (CNB), and surgical resection. Thirteen Sprague-Dawley rats were evaluated, nine of which received paritaprevir/ritonavir at 30/20 mg/kg of body weight by oral gavage daily for 4 or 5 days. Drug concentrations were measured using liquid chromatography-tandem mass spectrometry on samples collected via FNA (21G needle) with 1, 3, or 5 passes (FNA1, FNA3, and FNA5); via CNB (16G needle); and via surgical resection. Drug concentrations in plasma were also assessed. Analyses included noncompartmental pharmacokinetic analysis and use of Bland-Altman techniques. All liver tissue samples had higher paritaprevir and ritonavir concentrations than those in plasma. Resected samples, considered the benchmark measure, resulted in estimations of the highest values for the pharmacokinetic parameters of exposure (maximum concentration of drug in serum [Cmax] and area under the concentration-time curve from 0 to 24 h [AUC0-24]) for paritaprevir and ritonavir. Bland-Altman analyses showed that the best agreement occurred between tissue resection and CNB, with 15% bias, followed by FNA3 and FNA5, with 18% bias, and FNA1 and FNA3, with a 22% bias for paritaprevir. Paritaprevir and ritonavir are highly concentrated in rat liver. Further research is needed to validate FNA sampling for humans, with the possible derivation and application of correction factors for drug concentration measurements.


Assuntos
Fígado/metabolismo , Compostos Macrocíclicos/farmacocinética , Ritonavir/farmacocinética , Animais , Biópsia por Agulha Fina , Cromatografia Líquida , Ciclopropanos , Hepatócitos/metabolismo , Inativação Metabólica/fisiologia , Lactamas Macrocíclicas , Fígado/cirurgia , Masculino , Prolina/análogos & derivados , Ratos , Ratos Sprague-Dawley , Sulfonamidas , Espectrometria de Massas em Tandem
2.
J Biol Chem ; 290(28): 17074-84, 2015 Jul 10.
Artigo em Inglês | MEDLINE | ID: mdl-25969535

RESUMO

Tryptophan was substituted for residues in all four transmembrane domains of connexin32. Function was assayed using dual cell two-electrode voltage clamp after expression in Xenopus oocytes. Tryptophan substitution was poorly tolerated in all domains, with the greatest impact in TM1 and TM4. For instance, in TM1, 15 substitutions were made, six abolished coupling and five others significantly reduced function. Only TM2 and TM3 included a distinct helical face that lacked sensitivity to tryptophan substitution. Results were visualized on a comparative model of Cx32 hemichannel. In this model, a region midway through the membrane appears highly sensitive to tryptophan substitution and includes residues Arg-32, Ile-33, Met-34, and Val-35. In the modeled channel, pore-facing regions of TM1 and TM2 were highly sensitive to tryptophan substitution, whereas the lipid-facing regions of TM3 and TM4 were variably tolerant. Residues facing a putative intracellular water pocket (the IC pocket) were also highly sensitive to tryptophan substitution. Although future studies will be required to separate trafficking-defective mutants from those that alter channel function, a subset of interactions important for voltage gating was identified. Interactions important for voltage gating occurred mainly in the mid-region of the channel and focused on TM1. To determine whether results could be extrapolated to other connexins, TM1 of Cx43 was scanned revealing similar but not identical sensitivity to TM1 of Cx32.


Assuntos
Conexinas/química , Junções Comunicantes/química , Sequência de Aminoácidos , Substituição de Aminoácidos , Animais , Conexina 43/química , Conexina 43/genética , Conexina 43/metabolismo , Conexinas/genética , Conexinas/metabolismo , Feminino , Junções Comunicantes/metabolismo , Bicamadas Lipídicas/química , Bicamadas Lipídicas/metabolismo , Modelos Moleculares , Dados de Sequência Molecular , Mutagênese Sítio-Dirigida , Oócitos/metabolismo , Domínios e Motivos de Interação entre Proteínas , Subunidades Proteicas , Ratos , Proteínas Recombinantes/química , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Triptofano/química , Xenopus laevis , Proteína beta-1 de Junções Comunicantes
3.
Bioanalysis ; 8(13): 1353-63, 2016 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-27277877

RESUMO

AIM: Determination of paritaprevir and ritonavir in rat liver tissue samples. RESULTS: We successfully validated a UPLC-MS/MS method to measure paritaprevir and ritonavir in rat liver using deuterated internal standards (d8-paritapervir and d6-ritonavir). The method is linear from 20 to 20,000 and 5 to 10,000 pg on column for paritaprevir and ritonavir, respectively, and is normalized per milligram tissue. Interday and intraday variability ranged from 0.591 to 5.33% and accuracy ranged from -6.68 to 10.1% for quality control samples. The method was then applied to the measurement of paritaprevir and ritonavir in rat liver tissue samples from a pilot study. CONCLUSION: The validated method is suitable for measurement of paritaprevir and ritonavir within rat liver tissue samples for PK studies.


Assuntos
Antivirais/farmacocinética , Fígado/metabolismo , Compostos Macrocíclicos/farmacocinética , Inibidores de Proteases/farmacocinética , Ritonavir/farmacocinética , Espectrometria de Massas em Tandem/métodos , Animais , Antivirais/análise , Cromatografia Líquida de Alta Pressão/métodos , Ciclopropanos , Hepacivirus/efeitos dos fármacos , Hepacivirus/enzimologia , Hepatite C/tratamento farmacológico , Lactamas Macrocíclicas , Limite de Detecção , Compostos Macrocíclicos/análise , Masculino , Projetos Piloto , Prolina/análogos & derivados , Inibidores de Proteases/análise , Ratos , Ratos Sprague-Dawley , Ritonavir/análise , Sulfonamidas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA